Ontology highlight
ABSTRACT: Background
It has been suggested that sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduce the cardiorenal risk in patients with type 2 diabetes (T2D). The purpose of this study is to provide an update of all large cardiovascular outcome trials (CVOTs) with SGLT-2 inhibitors to assess their cardiorenal efficacy in patients with and without T2D.Methods
An electronic search up to 30 September 2021 was conducted in PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov. to determine eligible trials. We included CVOTs comparing any SGLT-2 inhibitor with placebo, reporting desired cardiovascular or renal outcomes and with a follow-up duration of at least 6 months.Results
Eleven CVOTs, with data from five SGLT-2 inhibitors (empagliflozin,
SUBMITTER: Giugliano D
PROVIDER: S-EPMC8680308 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature